此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

PEEL-224、长春新碱和替莫唑胺治疗儿科实体瘤 (PEEL-224)

2026年10月3日 更新者:Theodore Laetsch

新型拓扑异构酶 I 抑制剂 PEEL-224 作为单药并与长春新碱和替莫唑胺联合治疗难治性、进行性或复发性实体瘤儿童的 1/2 期临床试验

The phase 1 primary objective is to determine the pediatric recommended phase 2 dose (RP2D) of PEEL-224 as a single agent (phase 1A) and in combination with vincristine and temozolomide (phase 1B). The phase 2 primary objective is to estimate the objective response rate (ORR) in children with refractory, progressive and relapsed NBL and rhabdomyosarcoma (RMS) treated with the RP2D of PEEL-224 in combination with vincristine and temozolomide.

研究概览

详细说明

PEEL-224 will be a multi-institutional study conducted at pediatric cancer centers. Phase 1 will enroll approximately 24 subjects (maximum of 12 evaluable subjects in phase 1A and 12 evaluable subjects in phase 1B) between ages 1 to 18 years of age with a refractory, progressive or relapsed solid tumor. Phase 2 will enroll a maximum of 18 evaluable subjects with refractory, progressive or relapsed NBL and a maximum of 17 evaluable subjects with refractory, progressive or relapsed RMS. PEEL-224 will be administered at the assigned dose on days 1 and 8 of 21-day cycles as a single agent (phase 1A) or in combination with vincristine on days 1 and 8 and temozolomide on days 1-5 (phase 1B and phase 2). Subjects may continue protocol therapy for up to 24 cycles (approximately 18 months) in the absence of progressive disease or unacceptable toxicity. Subjects will be monitored with physical exams and labs on days 1 and 8 of each cycle and disease response assessments and patient reported outcome assessments will be performed after cycles 2, 4, 6, 9, 12, 18, and 24. During phase 1, PK blood samples will be drawn during cycle 1. The primary phase 1 endpoints are cycle 1 dose limiting toxicity (DLT) to define the RP2D. The primary phase 2 endpoint is best overall objective response to define the ORR.

研究类型

介入性

注册 (估计的)

59

阶段

  • 阶段2
  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

    • California
      • Los Angeles、California、美国、90048
        • 招聘中
        • Cedars-Sinai Medical Center
        • 首席研究员:
          • Leo Mascarhenhas, MD
      • San Francisco、California、美国、94143
        • 招聘中
        • University of California, San Francisco
        • 首席研究员:
          • Jennifer Michlitsch, MD
    • Massachusetts
      • Boston、Massachusetts、美国、02115
        • 招聘中
        • Boston Children's Hospital
        • 首席研究员:
          • David Shulman, MD
      • Boston、Massachusetts、美国、02215
        • 招聘中
        • Dana-Farber Cancer Institute
        • 首席研究员:
          • David Shulman, MD
    • Pennsylvania
      • Philadelphia、Pennsylvania、美国、19104
        • 招聘中
        • Children's Hospital of Philadelphia
        • 接触:
        • 首席研究员:
          • Jacquelyn Crane, MD
    • Texas
      • Houston、Texas、美国、77030
        • 招聘中
        • Texas Children's Hospital
        • 首席研究员:
          • Jennifer Foster, MD
    • Utah
      • Salt Lake City、Utah、美国、84132
        • 招聘中
        • University of Utah Hospital
        • 首席研究员:
          • Matthew Dietz, MD

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

1年 至 30年 (孩子、成人)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Age:

    • Phase 1: Age greater than or equal to 1 year and less than or equal to18 years
    • Phase 2 Neuroblastoma (NBL) cohort: Age greater than or equal to 1 year and less than or equal to 30 years
    • Phase 2 Rhabdomyosarcoma (RMS) cohort: Age greater than or equal to 1 year and less than or equal to18 years
  2. Diagnosis of:

    • Phase 1: Refractory, progressive or relapsed non-central nervous system (CNS) solid tumors who have received at least 1 line of upfront therapy. Patients must have had histologic verification of their malignancy at original diagnosis or relapse
    • Phase 2: Refractory, progressive or relapsed neuroblastoma (NBL) or rhabdomyosarcoma (RMS) who have received at least 1 line of upfront therapy. Patients must have had histologic verification of their malignancy at original diagnosis or relapse.
  3. Disease status:

    • Phase 1: evaluable or measurable disease
    • Phase 2, subjects with Neuroblastoma (NBL): evaluable or measurable disease by International Neuroblastoma Response Criteria (INRC); subjects with only bone marrow disease are not eligible
    • Phase 2, subjects with rhabdomyosarcoma (RMS): measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST)1.1.
  4. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2 (age greater than 16 years) or Lansky Performance Status of at least 60 (age less than 16 years).

  5. Females of childbearing potential must have a negative urine/serum pregnancy test.

  6. Adequate bone marrow function

    Hematologic requirements for all subjects on phase 1 and subjects on phase 2 without malignant infiltration of the bone marrow:

    • Absolute neutrophil count (ANC) greater than or equal to 750/mm3 (greater than or equal to 7 days since last dose of short acting myeloid growth factor medications (e.g. filgrastim) and greater than or equal to 14 days since last dose of long-acting myeloid medications (e.g. peg-filgrastim)
    • Platelet count ≥ 75,000 mm3 (greater than or equal to 14 days since last dose of thrombopoietin receptor agonist such as romiplostim and without platelet transfusion within previous 7 days)
    • Not refractory to packed red blood cell transfusions

    Hematologic requirements for subjects on phase 2 with malignant infiltration of the bone marrow:

    • Absolute neutrophil count (ANC) greater than or equal to 500/mm3 (greater than or equal to 7 days since last dose of short acting myeloid growth factor medications (e.g. filgrastim) and greater than or equal to 14 days since last dose of long-acting myeloid medications (e.g. peg-filgrastim))
    • Platelet count greater than or equal to 50,000/mm3 (greater than or equal to 14 days since last dose of thrombopoietin receptor agonist such as romiplostim and without platelet transfusion within previous 7 days)
    • Not refractory to packed red blood cell transfusions
    • Patients on phase 2 with malignant infiltration of the bone marrow will not be evaluable for hematologic toxicity.
  7. Adequate renal function as evidenced by creatinine clearance as calculated by the Schwartz equation (see below), radioisotope glomerular filtration rate (GFR) greater than or equal to 70 mL/min/1.73 m2, or maximum serum creatinine as below:

    Age Maximum Serum Creatinine (mg/dL)

    Male Female 1 to less than 2 years 0.6 0.6 2 to less than 6 years 0.8 0.8 6 to less than 10 years 1 1 10 to less than 13 years 1.2 1.2 13 to less than 16 years 1.5 1.4 greater than 16 years 1.7 1.4 Threshold derived from the Schwartz formula for estimating glomerular filtration rate (GFR) (Schwartz et al., J.Peds, 106:522,1985) utilizing child length and stature data published by the CDC The Schwartz equation for subjects less than 18 years of age: eGFR (mL/min/1.73 m2) = 0.413 x [height (cm)/serum creatinine (mg/dL)]

  8. Adequate liver function

    • Aspartate Aminotransferase (AST/SGOT): less than or equal to 3 times the upper limit of normal (ULN) or less than or equal to 5 the upper limit of normal if attributable to disease involvement. For the purpose of this study, the upper limit of normal (ULN) for Aspartate Aminotransferase (AST) is 50 U/L.
    • Alanine Aminotransferase (ALT/SGPT): less than or equal to 3 times the ULN or less than or equal to 5 the upper limit of normal if attributable to disease involvement. For the purpose of this study, the upper limit of normal (ULN) for Alanine Aminotransferase (ALT) is 45 U/L.
    • Total bilirubin: less than or equal to 1.5 times the upper limit of normal with the exception of patients with Gilbert's syndrome who must have bilirubin less than 3X institutional upper limit of normal (ULN).
  9. Prior Therapy: Patients must have had resolution of acute toxic effects of prior therapy to grade less than or equal to 1 according to the National Cancer Institute (NCI) common terminology criteria for adverse events (CTCAE) v 5.0 except organ function as noted above, adverse events (AE) that are considered clinically non-significant (i.e. alopecia), or controlled on supportive care (i.e. nausea/vomiting, hypothyroidism). Patients must meet the following minimum washout periods prior to enrollment:

    • Myelosuppressive chemotherapy: At least 14 days after the last dose of myelosuppressive chemotherapy

    • Small molecule targeted therapy: At least 7 days following the last dose of a small molecule targeted agent.

    • Antibody therapy: At least 21 days following the last dose of antibody including anti-GD2 monoclonal antibody.

    • Cellular therapy: At least 42 days following completion of a cellular therapy agent (e.g. modified T cells, NK cells, dendritic cells)

    • Autologous hematopoietic stem cell transplant and stem cell boost: Subjects must be at least 60 days from day 0 of an autologous stem cell transplant or stem cell boost.

    • Myeloid growth factors: At least 7 days following short-acting myeloid growth factor (e.g. filgrastim) and at least 14 days following the last dose of long-acting myeloid growth factor (e.g. peg-filgrastim)

    • Thrombopoietin receptor agonists: At least 14 days following last dose of thrombopoietin receptor agonist such as romiplostim

    • Interleukins, interferons, and cytokines (other than hematopoietic growth factors): At least 21 days following the completion of interleukins, interferon, or cytokines, including IL-2

    • Radiotherapy:

      • At least 14 days after limited field radiation therapy;
      • At least 90 days after total body irradiation, craniospinal radiotherapy; or radiation to greater than 50% of pelvis;
      • At least 42 days must have elapsed if other substantial BM radiation.
    • Radiopharmaceutical therapy (e.g. radiolabeled antibody, 131I- MIBG): At least 42 days after radiopharmaceutical therapy

    • Major Surgery: At least 2 weeks from prior major surgical procedure. Note: Biopsy, CNS shunt placement/revision, and central line placement/removal are not considered major.

    • Strong CYP1A2 and/or CYP3A4 inhibitors and/or inducers: At least 14 days following use of a strong CYP1A2 and/or CYP3A4 inhibitor and/or inducer. See Appendix 1 for examples. (Note that levofloxacin is permitted when clinically indicated)

  10. Prior treatment with irinotecan and/or temozolomide is permitted.

  11. Female patients of reproductive potential must agree to use a highly effective contraceptive method for the duration of study therapy and for at least six months after the final dose of PEEL-224. Males of reproductive potential with a female partner of child-bearing potential must use a highly effective for the duration of the study and for at least six months after the final dose of PEEL-224.

  12. Subjects must agree to use sun protective measures while receiving treatment and for 4 weeks after the last dose of PEEL-224

  13. Parental/guardian permission (informed consent) and if appropriate, child assent.

Exclusion Criteria:

  1. Prior treatment with PEEL-224.
  2. Subjects receiving any other anti-cancer agents.
  3. Subjects with primary central nervous system (CNS) solid tumors or central nervous system (CNS) metastatic disease.
  4. Subjects with prior allogeneic stem cell or solid organ transplantation.
  5. Pregnant or lactating females.
  6. Subjects with a known history of human immunodeficiency virus (HIV), hepatitis B, and/or hepatitis C (testing not required as part of screening).
  7. Subjects with symptomatic congestive heart failure.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:非随机化
  • 介入模型:顺序分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:PEEL-224

Phase 1A will test the safety, tolerability and PK profile of PEEL-224 as a single agent in pediatric patients with refractory, progressive and relapsed solid tumors.

PEEL-224 (PEG-[SN22]4) is a novel topoisomerase I inhibitor

实验性的:PEEL-224, Vincristine, and Temozolomide

Phase 1B will test the safety, tolerability and pharmacokinetic profile of PEEL-224 in combination with vincristine and temozolomide in pediatric subjects with refractory, progressive and relapsed solid tumors. Phase 2 will preliminary evaluate the activity profile of PEEL-224 in combination with vincristine and temozolomide in pediatric patients with refractory, progressive and relapsed NBL and RMS.

PEEL-224 (PEG-[SN22]4) is a novel topoisomerase I inhibitor

Vincristine is an inhibitor of microtubular formation which is approved by the Food and Drug Administration (FDA) and is commercially available.

Temozolomide is an alkylating agent which is approved by the FDA and is commercially available.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Phase 1A and Phase 1B: Number of participants who experience a dose limiting toxicity (DLT)
大体时间:1 month

The observation of a dose-limiting toxicity (DLT) or lack of observation of DLT in the period between treatment initiation up to initiation of cycle 2 treatment. A dose limiting toxicity (DLT) describes side effects of a drug or other treatment that are serious enough to prevent an increase in dose or level of that treatment.

1 month
Phase 2 Neuroblastoma Cohort (NBL): Number of paricptants who achieve a complete response (CR), partial response (PR), or minor response (MR)
大体时间:2 years

Objective response as assessed by the Revised International Neuroblastoma Response Criteria (INRC). Response is defined as complete response (CR), partial response (PR) or minor response (MR), using best response measured at any point prior to local control.

2 years
Phase 2 Rhabdomyosarcoma (RMS) Cohort: Number of participants who achieve a complete response (CR) or partial response (PR)
大体时间:2 years

Objective response as assessed by Response Evaluation Criteria In Solid Tumors (RECIST) 1.1. Response is defined as complete response (CR) or partial response (PR), using best response measured at any point prior to local control.

2 years

次要结果测量

结果测量
措施说明
大体时间
Number of subjects with an Adverse Event (AE) of greater than or equal to grade 3 at least possibly attributable to study treatment
大体时间:30 days after last dose

Adverse Events (AEs) will be graded by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

30 days after last dose
Area under the plasma-concentration-time-curve of PEEL-224
大体时间:1 month

To characterize the pharmacokinetic (PK) profile of free SN22 and SN22 bound to PEG (PEEL-224)

1 month
Number of participants demonstrating anti-tumor activity of PEEL-224
大体时间:2 years

To preliminarily evaluate antitumor activity of PEEL-224 by estimating event-free survival (EFS)

2 years
Number of participants demonstrating anti-tumor activity of the combination of PEEL-224, vincristine and temozolomide
大体时间:2 years

To preliminarily evaluate antitumor activity of the combination of PEEL-224, vincristine and temozolomide by estimating event-free survival (EFS )

2 years

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Jacquelyn Crane, MD、Children's Hospital of Philadelphia

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2025年3月23日

初级完成 (估计的)

2030年4月1日

研究完成 (估计的)

2031年4月1日

研究注册日期

首次提交

2024年12月2日

首先提交符合 QC 标准的

2024年12月5日

首次发布 (实际的)

2024年12月6日

研究记录更新

最后更新发布 (实际的)

2026年10月6日

上次提交的符合 QC 标准的更新

2026年10月3日

最后验证

2026年10月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅